VAUGHAN, ON, Oct. 3, 2018 /CNW/ - CannTrust Holdings Inc.
("CannTrust" or the "Company", TSX: TRST), one of Canada's leading licensed producers and most
trusted brands of medical cannabis, announced today that it
celebrates serving 50,000 patients, and is growing at an
unprecedented rate. CannTrust is capturing 36 percent of all newly
registered patients in Canada,
based on the most recent quarterly data provided by Health
Canada.
"CannTrust is proud to help more than 50,000 Canadians address
their health issues, and we anticipate continued strong growth,"
says Brad Rogers, President of
CannTrust. "We are experiencing a steady, continuous increase week
over week, month over month, due to continued partnerships with
thousands of healthcare practitioners across the country."
"Healthcare practitioners know and trust CannTrust products,
because they can prescribe an accurate dose, gradually increase the
dose, and gauge efficacy," says Rogers. "With CannTrust you know
exactly what you are going to get every single time."
Our CannTrust promise to patients:
- We are committed to offering quality cannabis products at
industry leading affordable prices due to our unique perpetual
harvest technology used at our advanced greenhouse in Niagara.
- We are committed to producing standardized cannabis products,
so you can be confident that you will receive the same standardized
product every time.
- We are committed to having our CBD, 1:1 and THC based oil drops
and vegan capsules always in stock, as well as an excellent variety
of dried flower.
- We are committed to ensuring access to affordable medical
cannabis. We will be absorbing the excise tax on medical cannabis
that is planned for October 17, so
you will not have to pay more for medical cannabis due to this
tax.
- We are committed to supporting our patients with financial
needs through our patient assistance program.
- We are committed to supporting our veterans through our
veterans' support program.
- We are committed to ensuring our patients can get their
medication in a timely fashion through our same-day Trust Delivery
service for patients in the GTA, and through Purolator or Canada
Post for those across the country.
- We are committed to innovation. Our product development teams
along with our global pharma partner, Apotex Inc., are diligently
developing new products and dosage formats to improve your
experience.
- We are committed to advancing research on the use and efficacy
of cannabis. We are currently involved in two randomized placebo
controlled clinical trials; a chronic pain trial at McMaster University in Hamilton, Ontario, and an ALS trial with
Australia's Gold Coast University
Hospital, with several other Canadian studies being developed.
"We remain dedicated to our medical cannabis patients," says
Eric Paul, CannTrust's Co-Founder
and Chairman of the Board. "Together, we have changed the medical
landscape in Canada, and as the
industry evolves, CannTrust looks forward to continuing our
important work in supporting the good health and well-being of
Canadians."
About CannTrust
Since its inception in 2014, CannTrust
has led the Canadian market in producing standardized cannabis
products.
As a federally regulated licensed producer, CannTrust brings
more than 40 years of pharmacy and healthcare experience to the
medical cannabis industry. CannTrust currently operates its 450,000
sq. ft. Niagara Perpetual Harvest Facility. The 600,000 sq. ft.
greenhouse expansion has begun and is fully funded. CannTrust's
broad product portfolio is prepared and packaged at the 60,000 sq.
ft. manufacturing Centre of excellence in Vaughan, Ontario.
CannTrust is committed to research and innovation, as well as
contributing to the growing body of evidence-based research
regarding the use and efficacy of cannabis. Its product development
teams along with its exclusive global pharma partner, Apotex Inc.,
are diligently innovating and developing products that will make it
easier for patients to use medical cannabis. CannTrust supports
ongoing patient education about medical cannabis and has a
compassionate use program to support patients with financial
needs.
For more information, please visit: www.canntrust.ca.
Forward Looking Statements
This press release contains
"forward-looking information" within the meaning of applicable
Canadian securities legislation which are based upon CannTrust's
current internal expectations, estimates, projections, assumptions
and beliefs and views of future events. Forward-looking information
can be identified by the use of forward-looking terminology such as
"expect", "likely", "may", "will", "should", "intend",
"anticipate", "potential", "proposed", "estimate" and other similar
words, including negative and grammatical variations thereof, or
statements that certain events or conditions "may", "would" or
"will" happen, or by discussions of strategy.
The forward-looking information in this news release is based
upon the expectations, estimates, projections, assumptions and
views of future events which management believes to be reasonable
in the circumstances. Forward-looking information includes
estimates, plans, expectations, opinions, forecasts, projections,
targets, guidance or other statements that are not statements of
fact. Forward-looking statements in this news release include, but
are not limited to, statements with respect to internal
expectations, expectations with respect to actual production
volumes, expectations for future growing capacity and the
completion of any capital project or expansions. Forward-looking
statements necessarily involve known and unknown risks, including,
without limitation, risks associated with general economic
conditions; adverse industry events; loss of markets; future
legislative and regulatory developments; inability to access
sufficient capital from internal and external sources, and/or
inability to access sufficient capital on favourable terms; the
medical cannabis industry in Canada generally; the
ability of CannTrust to implement its business strategies;
competition; crop failure; and other risks.
Any forward-looking information speaks only as of the date on
which it is made, and, except as required by law, CannTrust does
not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for CannTrust to predict all
such factors. When considering these forward-looking statements,
readers should keep in mind the risk factors and other cautionary
statements in CannTrust's Annual Information Form dated
March 29, 2018 (the "AIF") and filed
with the applicable Canadian securities regulatory authorities on
SEDAR at www.sedar.com. The risk factors and other factors
noted in the AIF could cause actual events or results to differ
materially from those described in any forward-looking
information.
The TSX does not accept responsibility for the adequacy or
accuracy of this release.
Copyright © 2017 CannTrust Holdings Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/canntrust-continues-patient-growth-celebrates-significant-milestone-and-ongoing-momentum-300723445.html
SOURCE CannTrust Holdings Inc.